Aarti Industries FY26 Results: Revenue up 12%, EBITDA rises 15% on volume growth
- Consolidated revenue grew 12% YoY to ₹9,018 crore in FY26
- EBITDA rose 15% to ₹1,172 crore; net profit up 27% to ₹419 crore
- Volume growth exceeded 30% despite margin pressures from competition
- Signed $150mn agrochemical supply deal and ₹200-250cr backward integration pact
- Debt-to-equity ratio increased to 0.74 due to working capital needs

*this image is generated using AI for illustrative purposes only.
Aarti Industries reported a 12% year-on-year increase in consolidated revenue to ₹9,018 crore for FY26, driven by over 30% volume growth across key value chains. EBITDA expanded 15% to ₹1,172 crore, while net profit rose 27% to ₹419 crore compared to the previous fiscal year.
The specialty chemicals manufacturer navigated a volatile macro environment marked by US tariff announcements and geopolitical conflicts. Despite these headwinds, the company secured long-term supply contracts and executed backward integration projects to strengthen its market position.
Financial Performance
The company’s financial results for FY26 reflect robust top-line growth supported by higher asset utilization in Nitro Chloro Benzenes (NCB), Di-Chlorobenzenes (DCB), and MMA segments.
| Metric | FY25 | FY26 | Change |
|---|---|---|---|
| Revenue | ₹8,046 crore | ₹9,018 crore | +12% |
| EBITDA | ₹1,016 crore | ₹1,172 crore | +15% |
| Net Profit | ₹331 crore | ₹419 crore | +27% |
| Capex | ₹1,372 crore | ₹1,125 crore | -18% |
Net fixed assets stood at ₹6,399 crore, a marginal increase from ₹6,377 crore in FY25. The debt-to-equity ratio rose to 0.74 from 0.62, attributed to increased working capital requirements due to rising raw material prices amid West Asia conflicts.
What the Numbers Show
Revenue growth significantly outpaced EBITDA expansion, indicating margin compression during the period. While volumes grew over 30%, the company faced continued margin pressure from competitive landscapes and input cost inflation. Additionally, net profit benefited from exceptional items, including ₹29 crore from favorable IT appeal rulings, partially offset by ₹22 crore in one-off write-offs related to new labor code impacts.
Operational Highlights
Capacity utilization improved across major product groups:
- NCB utilization reached 86% (up 9% YoY)
- DCB utilization hit 80% (up 9% YoY)
- MMA/Fuel Additives utilization stood at 86% with capacity scaled up to 360 kTPA in Q1FY27
Energy applications contributed 43% of total revenue, up from 36% in FY25, driven by favorable blending economics and expanded capacities in US and EMEA regions. Agrochemicals remained stable at 18% share, though margins stayed under pressure.
Strategic Developments
In March 2026, Aarti Industries entered into a material amendment for an exclusive backward integration contract with a global chemical major. This involves an investment of ₹200–250 crore over two years to manufacture feedstock currently supplied by the customer, aiming to optimize opex and freight over a 15-year period.
The company also signed a $150 million multi-year supply agreement with a global agrochemical innovator until March 2030. This contract supports higher capacity utilization without significant capex, with volume growth expected from FY27.
Sustainability & Outlook
Aarti Industries achieved a Platinum rating from EcoVadis in June 2026, placing it in the top 1% of global chemical companies. Renewable energy contribution exceeded 21% of total power purchased, with plans to reach 70% by end-FY27.
Near-term EBITDA growth drivers include cost optimization initiatives targeting ₹150–200 crore savings and volume ramp-ups expected to contribute ₹350–550 crore. Key projects like Zone IV and joint ventures with Augene and Re Aarti are slated for commissioning in FY27.
Historical Stock Returns for Aarti Industries
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.76% | +1.44% | -5.72% | +15.45% | +27.86% | 0.0% |
How will the 15-year backward integration contract with the global chemical major impact Aarti Industries' long-term EBITDA margins and operational flexibility?
What specific strategies is Aarti Industries employing to mitigate margin compression in the agrochemicals segment amid persistent input cost inflation?
Will the commissioning of Zone IV and joint ventures with Augene and Re Aarti in FY27 be sufficient to offset the working capital strain indicated by the rising debt-to-equity ratio?

































